Biotechnology company Tenaya Therapeutics has announced its plans to raise USD 75 million consisting of 22.6 million common shares at USD 2.6 per share via an underwritten public offering and it is offering pre-funded warrants as an alternative to common stock to purchase up to 6.2 million shares at USD 0.001 lower than the public offering price. The firm will also offer a 30-day option to purchase an additional up to 4,327,500 in common shares at the public offering price. The firm’s share price rose 8.8% to close at USD 3.19 on the 16th of November.
Moreover, joint book-running managers of the offering include Morgan Stanley and Piper Sandler while co-lead managers for the offering will be H.C. Wainwright & Co. and Chardan.
The new funds along with its existing cash balance will be used towards advancing its lead products, TN-201 (MYBPC3 gene therapy), TN-301 (HDAC6i small molecule), and TN-401 (PKP2 gene therapy) towards clinical and preclinical stages. In addition, the funds will be used to develop early research programs, improve its platform, for operations, and working capital and corporate expenses.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.